Objective:
To review next-generation biologics and gene therapies aimed at improving treatment durability and reducing burden in neovascular age-related macular degeneration (nAMD), highlighting their potential impact on patient care.
Key Findings:
- New therapies like aflibercept 8 mg and faricimab offer longer dosing intervals, potentially improving patient adherence.
- Multitargeted therapies are being developed to address multiple pathways involved in nAMD, which may enhance treatment efficacy.
- Tarcocimab tedromer showed noninferior visual acuity gains compared to aflibercept in trials, indicating its viability as an alternative treatment.
- Axpaxli demonstrated superior outcomes compared to aflibercept in the SOL-1 trial, suggesting a promising new option for patients.
Interpretation:
The evolving landscape of nAMD treatments highlights the potential for improved patient outcomes through innovative therapies that target multiple biological pathways and extend treatment intervals, which could significantly enhance quality of life.
Limitations:
- Some therapies are still in early-phase trials, limiting available data on long-term efficacy and safety, which raises concerns about their readiness for clinical use.
- Certain investigational agents have been discontinued due to unmet primary endpoints, underscoring the challenges in developing effective treatments.
Conclusion:
Next-generation therapies for nAMD show promise in enhancing treatment efficacy and reducing patient burden, with several candidates progressing through clinical trials, emphasizing the need for continued research and development.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.